Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-20

Study Completion Date

2020-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this phase 2 study, we aim to evaluate the effects and safety of adjuvant apatinib therapy for the patients who underwent R0 resection for hepatocellular carcinoma with portal vein tumor thrombus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

NCT01033578

Hepatocellular Carcinoma

UNKNOWN NA

The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

NCT03511703

Hepatocellular Carcinoma

UNKNOWN PHASE2

The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus

NCT03520257

Hepatocellular Carcinoma

UNKNOWN PHASE2

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

NCT06349317

Hepatocellular Carcinoma

RECRUITING PHASE2

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

NCT03510416

Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Portal vein tumor thrombus (PVTT) is one of the characteristics of advanced stage for patients with hepatocellular carcinoma (HCC). There's limited treatment choice for these patients. Even for those who underwent curative resection (R0 resection), the recurrence rate was extremely high. Apatinib is a highly selective VEGFR2 inhibitor and reduces the angiogenesis of tumor efficiently, which had been proven effective in many solid tumors, is a Chinese domestic TKI targeting vascular endothelial growth factor receptor. Phase 2 study of apatinib for patients with advanced HCC had shown signals of clinical efficacy and modest safety. In this study, we aim to evaluate the effects and safety of adjuvant apatinib therapy for the patients who underwent R0 resection for HCC with PVTT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Hepatocellular

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apatinib

Apatinib mesylate tablets 500 mg po qd.

Group Type EXPERIMENTAL

Apatinib

Intervention Type DRUG

Apatinib mesylate tablets 500 mg po qd.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apatinib

Apatinib mesylate tablets 500 mg po qd.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged from 18-70 years.
2. HCC diagnosis confirmed by pathological examination who did not receive anti-tumor treatment (anti-tumor treatment including but not limited to: local ablation therapy, TACE, radiation therapy, chemotherapy, targeted drug therapy, etc.)
3. Underwent radical resection for hepatocellular carcinoma with portal vein tumor thrombus, as assessed by preoperative imaging or intraoperative findings, within 4 weeks
4. Child-Pugh class: A or B7
5. The ECOG: 0-1 points
6. The expected survival time ≥ 6 months.
7. Main organs function is normal including:

* blood routine examination

* HB ≥ 90 g/L
* ANC ≥ 1.5×109 /L
* PLT ≥ 80×109/L
* biochemical test

* ALB ≥ 29 g/L
* ALT\<3 ULN and AST\< 3 ULN
* TBIL ≤ 1.5 ULN
* Serum creatinine ≤ 1.5 ULN；
8. Women of childbearing age must have pregnancy tests (serum or urine) within 7 days prior to admission, and the results are negative and are willing to use appropriate methods of contraception at 8 weeks after the trial and at the end of the test. For men, surgical sterilization should be applied, or consent to the appropriate method of contraception 8 weeks after the trial and at the end of the trial;
9. subjects voluntarily joined the study, signed informed consent, good compliance, and followed up.

Exclusion Criteria

1. Hepatic duct carcinoma、mixed cell carcinoma and fiberboard layer cell carcinoma which have confirmed; Past (5 years) or current with other malignant tumor, except skin basal cell carcinoma and cervical carcinoma in situ.
2. Patients with hypertension who are unable to fall within normal range by antihypertensive medications (systolic pressure \> 140 mmHg, diastolic pressure \> 90 mmHg).
3. With the second level of myocardial ischemia or myocardial infarction, poor control of the arrhythmia (including QTc interval = 450 ms, male female = 470 ms).
4. Factors that affect oral medication, such as inability to swallow, chronic diarrhea and intestinal obstruction, which significantly affect the use and absorption of drugs.
5. Ascites with clinical symptoms requires therapeutic peritoneal paracentesis or drainage.
6. In the past 6 months, with the history of alimentary tract hemorrhage or definite gastrointestinal bleeding tendency, such as: the risk of bleeding esophageal varices, local active ulcerative lesions, fecal occult blood; For those with fecal occult blood (+), gastroscopy is required.
7. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before entry;
8. Postoperative complications were not relieved.
9. Abnormal coagulation function (INR \> 1.5 or prothrombin time (PT) \> ULN+4 seconds), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy;
10. Past and present pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment;
11. Urine routine showed that urinary protein is more than + + or confirmed 24 hours urine protein is more than 1.0 g;
12. Symptomatic metastasis of the central nervous system;
13. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives;
14. Patient with mental illness or a history of psychotropic substance abuse;
15. HIV infection;
16. Before operation, AFP or PIVKA-2 increased, but not decreased to normal range;
17. HBV-DNA\>10\^3 copys/ml；
18. Other conditions that the investigators considered that not unsuitable for inclusion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No